Standard Strength: 5 mg BPC-157 + 5 mg TB-500 (10 mg total)
Advanced Strength: 10 mg BPC-157 + 10 mg TB-500 (20 mg total)
Oral Backbone: RECOVER™ — 500 mcg BPC-157 + 2 mg GHK-Cu + 500 mg carnosine staged-release capsule, 1 cap AM, 5 days on / 2 days off
Cytoprotective gastric pentadecapeptide. Potent angiogenic, endothelial-protective, GI-healing, and tendon/ligament-restorative peptide.
Synthetic Tβ4 fragment. Dominant in actin cytoskeleton regulation, cell migration, angiogenesis, and wound repair.
The Wolverine Blend creates a single injectable, stacked regenerative platform combining BPC-157’s GI/endothelial/tendon repair with TB-500’s actin-mediated cell migration and robust angiogenesis.
Angiogenesis/microvascular repair, fibroblast activation/collagen I synthesis, GI mucosal healing/barrier integrity, neuroprotective/endothelial modulation (NO/eNOS pathways).
Actin sequestration/G-actin binding/cell migration (keratinocytes, fibroblasts, myocytes), VEGF-driven angiogenesis, anti-inflammatory/anti-fibrotic (TNF-α, IL-6, neutrophil infiltration), tissue remodeling/collagen organization.
| Domain | BPC-157 | TB-500 | Synergistic Result |
|---|---|---|---|
| Angiogenesis | Organized microvascular | VEGF-driven vessels | Robust ordered re-perfusion |
| Actin/Migration | Fibroblast support | Direct G-actin | High-velocity tissue repopulation |
| Tendon/Ligament | Tendon-to-bone, collagen I | Collagen alignment, ↓adhesion | Stronger organized repair |
| GI/Endothelial | Strong | Weak–moderate | Systemic protection during loading |
| Inflammation | Anti-inflammatory/NO | Anti-inflammatory/anti-fibrotic | Lower chronic burden, better scars |
| Neurovascular | Neuroprotection, stability | Emerging neuroregenerative | Neuroinflammatory support |
Tendon/ligament healing, muscle/myofascial repair, improved tensile strength/collagen alignment, reduced recovery times.
Accelerated dermal closure, enhanced keratinocyte/fibroblast migration, improved scar quality, synergy with GHK-Cu, PRP/PRF, energy-based procedures.
BPC-157 GI/endothelial protection for patients on NSAIDs or under orthopedic stress. TB-500 vascular remodeling and anti-fibrotic actions.
| Option | Diluent | Concentration | Use |
|---|---|---|---|
| A — High | 2 mL BS | 5 mg/mL total (2.5/2.5) | Focal tendon/ligament |
| B — Moderate | 5 mL BS | 2 mg/mL total (1/1) | Mesotherapy, larger fields |
| C — Low | 10 mL BS | 1 mg/mL total (0.5/0.5) | Wide dermal, sensitive pts |
| Option | Diluent | Concentration | Use |
|---|---|---|---|
| A — High | 2 mL BS | 10 mg/mL total (5/5) | Experienced injectors, large athletes |
| B — Moderate | 5 mL BS | 4 mg/mL total (2/2) | Standard clinical |
| C — Conservative | 10 mL BS | 2 mg/mL total (1/1) | Older/comorbid, multi-site |
2–4 mg/mL, 0.1–0.3 mL/site, 3–6 sites, 1–4 mg/session, q7d × 4–6 wk
0.1–0.2 mL/site linear/fan, 1–3 mg/session, q5–7d × 3–4 wk
1–2 mg/mL, 1–3 mm depth, 1–1.5 cm grid, 0.5–2 mg/session, weekly × 3–6
0.25–0.5 mg SC, daily–3×/wk × 2–4 wk. Multi-site overuse, heavy training.
Peptide Protocol Portal does not recommend intra-articular injection of BPC-157 or TB-500.
Structural soft-tissue lesion? → YES → continue
Failed conservative care? → YES → injectable Wolverine
No failure yet? → RECOVER™ ± topical first
Rapid recovery needed (athlete/occupation)? → Wolverine + RECOVER™ + PT/PRP
Contraindications? → Avoid/modify/refer
Localization: Focal tendon/ligament → Peri-tendinous • Diffuse muscle/fascia → SC/IM + meso • Dermal/scar → Mesotherapy • Systemic/multi-site → SC micro + RECOVER™
Severity: Mild → RECOVER™ ± low-dose SC • Moderate → RECOVER™ + targeted 1–3 mg • Severe → RECOVER™ + 3–6 mg + PRP/shockwave/PT
Patient: Older/comorbid → lower conc, slower titration • High-output athlete → more aggressive, close monitoring
Tendon: Acute <3 mo → RECOVER™ + Wolverine q7d × 3–4. Chronic >3 mo → q7d × 4–6 + PT + PRP
Ligament: Grade I–II → RECOVER™ + brace + Wolverine q7d × 3–4. Grade III → surgical eval ± peri-op support
Muscle/Fascia: Partial → RECOVER™ + SC/IM Wolverine ± mesotherapy. Large tear → imaging + surgical consult, Wolverine adjunct only
RECOVER™ 1 cap AM 5/2 × 12 wk + Wolverine Standard 2 mg/session (0.2 mL × 5 sites), q7–10d × 4–6. Adjunctive: eccentric training, bracing, shockwave/PRP.
RECOVER™ × 8–12 wk + Wolverine 3–4 mg/session, fan along MCL, 6–8 sites, q7d × 3–4. Hinged brace, PT, return-to-play testing.
RECOVER™ once oral tolerated × 12 wk + Wolverine 2–3 mg around tendon footprint, q7–14d × 3–4 (surgeon-approved). PT, PRP, biologics.
RECOVER™ × 8–12 wk + Wolverine meso 0.5–1.5 mg intradermal grid, q2–4 wk × 3–4. GHK-Cu topical, PRiVIVE™, RF/microneedling/laser.
RECOVER™ + optional REVIVE™/REBALANCE™ + SC micro 0.5–1 mg q48h × 2–4 wk + targeted peri-tendinous 2–3 mg weekly. Load management, nutrition, sleep.
Subjective: Pain scores, functional scales, recovery time, GI tolerance. Objective: Ultrasound/MRI follow-up, ROM/strength, CRP/ESR, LFTs in high-risk.
Typically mild: injection-site erythema/discomfort, transient fatigue/headache, local edema if dose/volume excessive.
This document is provided solely for educational and informational purposes. BPC-157, TB-500, and Wolverine Blend are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.